This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benlloch, S. Articles by Massutí, B. Search for Related Content PubMed PubMed Citation Articles by Benlloch, S. Articles by Massutí, B.

JMD 2006, Vol. 8, No. 5
Copyright © 2006 American Society for Investigative Pathology & Association for Molecular Pathology

Technical Advance

Detection of BRAF V600E Mutation in Colorectal Cancer

Comparison of Automatic Sequencing and Real-Time Chemistry Methodology

Susana Benlloch^*, Artemio Payá, Cristina Alenda, Xavier Bessa, Montserrat Andreu, Rodrigo Jover, Antoni Castells^¶, Xavier Llor^||, F. Ignacio Aranda and Bartomeu Massutí^**

From the Departments of Investigation, * Pathology, Gastroenterology, and Oncology, ** Hospital General Universitario de Alicante, Alicante; Department of Gastroenterology, Hospital del Mar, Barcelona; Department of Gastroenterology, ^|| Hospital Universitario Germans Trias i Pujol, Badalona; and Department of Gastroenterology, ^¶ Institut de Malalties Digestives, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain

Abstract

Mutation V600E of BRAF, a kinase-encoding gene from the RAS/RAF/MAPK pathway, in colorectal carcinoma (CRC) suggests a sporadic origin of the disease, providing an exclusion criterion for hereditary nonpolyposis colorectal cancer. Here we describe detection of this mutation by real-time chemistry TaqMan MGB probes, confirmed by direct DNA sequencing as the gold standard. DNA was extracted from paraffin-embedded tissue from 112 tumors obtained from the EPICOLON study. Seventy-two tumors were CRC with defective DNA mismatch repair (MMR; microsatellite instability and/or loss of protein expression by immunohistochemical analysis), and 40 were proficient MMR controls. BRAF mutation was detected in 20/72 (27.8%) CRC with defective MMR and in 3/40 (7.5%) proficient MMR controls (P = 0.011). BRAF mutation was detected in 19/51 (37.3%) tumors with loss of MLH1 expression and in none of the tumors with loss of MSH2 expression (0/13). BRAF mutation was not found in cases with germline mutation of MLH1 (4/112) or MSH2 (3/112) genes. The sensitivity and specificity of our real-time chemistry were both 100% for detecting the V600E mutation. Because real-time chemistry methodology has advantages in cost, time, and labor, we consider it a valuable alternative to automatic direct sequencing, particularly for serial measurements.

This article has been cited by other articles:

				A. Paya, C. Alenda, L. Perez-Carbonell, E. Rojas, J.-L. Soto, C. Guillen, A. Castillejo, V. M. Barbera, A. Carrato, A. Castells, et al. Utility of p16 Immunohistochemistry for the Identification of Lynch Syndrome Clin. Cancer Res., May 1, 2009; 15(9): 3156 - 3162. [Abstract] [Full Text] [PDF]

				M. Pichler, M. Balic, E. Stadelmeyer, C. Ausch, M. Wild, C. Guelly, T. Bauernhofer, H. Samonigg, G. Hoefler, and N. Dandachi Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors J. Mol. Diagn., March 1, 2009; 11(2): 140 - 147. [Abstract] [Full Text] [PDF]

				D Ramsoekh, A Wagner, M E van Leerdam, W N M Dinjens, E W Steyerberg, D J J Halley, E J Kuipers, and D Dooijes A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting Gut, November 1, 2008; 57(11): 1539 - 1544. [Abstract] [Full Text] [PDF]